These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12618896)

  • 21. Recombinant leukocyte A interferon with doxorubicin. A phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma.
    Creagan ET; Long HJ; Frytak S; Moertel CG
    Cancer; 1988 Jan; 61(1):19-22. PubMed ID: 2825959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma.
    Falkson CI; Falkson G
    Oncology; 1999 Oct; 57(3):232-5. PubMed ID: 10545792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
    JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil].
    Katsuramaki T; Furuhata T; Kimura Y; Yamaguchi K; Ohmura T; Hata F; Mukaiya M; Hirata K
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1801-4. PubMed ID: 12402433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival.
    Patt YZ; Charnsangavej C; Yoffe B; Smith R; Lawrence D; Chuang V; Carrasco H; Roh M; Chase J; Fischer H
    J Clin Oncol; 1994 Jun; 12(6):1204-11. PubMed ID: 8201383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
    Leung TW; Patt YZ; Lau WY; Ho SK; Yu SC; Chan AT; Mok TS; Yeo W; Liew CT; Leung NW; Tang AM; Johnson PJ
    Clin Cancer Res; 1999 Jul; 5(7):1676-81. PubMed ID: 10430068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined floxuridine and cisplatin in a fourteen day infusion. Phase I study.
    Lokich J; Anderson N; Bern M; Wallach S; Moore C; Williams D; Umprain V
    Cancer; 1988 Dec; 62(11):2309-12. PubMed ID: 2972354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
    Hong RL; Tseng YL
    Cancer Chemother Pharmacol; 2003 May; 51(5):433-8. PubMed ID: 12736762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma.
    Strumberg D; Erhard J; Harstrick A; Klaassen U; Müller C; Eberhardt W; Wilke H; Seeber S
    Eur J Cancer; 1998 Jul; 34(8):1290-2. PubMed ID: 9849493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study.
    Vitale FV; Romeo P; Vasta F; Panebianco V; Calì S; Rotondo S; Ferraù F; La Greca M
    Anticancer Res; 2007; 27(6B):4077-81. PubMed ID: 18225574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intra-arterial chemotherapy using an implantable infusion pump in liver metastases of colorectal tumors and hepatomas].
    Balch CM; Urist MM
    Chirurg; 1984 Aug; 55(8):485-93. PubMed ID: 6092009
    [No Abstract]   [Full Text] [Related]  

  • 32. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group.
    Ortega JA; Krailo MD; Haas JE; King DR; Ablin AR; Quinn JJ; Feusner J; Campbell JR; Lloyd DA; Cherlow J
    J Clin Oncol; 1991 Dec; 9(12):2167-76. PubMed ID: 1720452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
    Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
    J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II evaluation of doxorubicin plus bleomycin in hepatocellular carcinoma: a Southeastern Cancer Study Group trial.
    Ravry MJ; Omura GA; Bartolucci AA
    Cancer Treat Rep; 1984 Dec; 68(12):1517-8. PubMed ID: 6210143
    [No Abstract]   [Full Text] [Related]  

  • 35. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of alpha 2-interferon plus doxorubicin in patients with solid tumors.
    Sarosy GA; Brown TD; Von Hoff DD; Spiegel RJ; Golando JP; Beougher KL; Kuhn JG; Kisner DL
    Cancer Res; 1986 Oct; 46(10):5368-71. PubMed ID: 3756887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study.
    Valle JW; Dangoor A; Beech J; Sherlock DJ; Lee SM; Scarffe JH; Swindell R; Ranson M
    Br J Cancer; 2005 Feb; 92(4):628-30. PubMed ID: 15700038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma.
    Shakado S; Iwata K; Tsuchiya N; Kunimoto H; Yotsumoto K; Fukunaga A; Kuno S; Tanaka T; Sakurai K; Iwashita H; Hirano G; Yokoyama K; Morihara D; Nishizawa S; Takeyama Y; Irie M; Sohda T; Kora S; Yoshimitsu K; Sakisaka S
    Hepatogastroenterology; 2014 May; 61(131):557-62. PubMed ID: 26176035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
    Kuroda M; Kobayashi Y; Urawa N; Yamamoto M; Mifuji R; Araki J; Tanaka H; Horiike S; Itani T; Furjita N; Konishi M; Iwasa M; Kaito M; Adachi Y
    Hepatogastroenterology; 2007 Mar; 54(74):518-21. PubMed ID: 17523311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.